Research programme: immunotherapy - sigma-tauAlternative Names: Pentraxin 3; PTX 3
Latest Information Update: 23 Aug 2010
At a glance
- Originator sigma-tau SpA
- Class Proteins
- Mechanism of Action Complement activation stimulants; Cytokine stimulants; Cytomegalovirus replication inhibitors; Transcription factor stimulants; Viral fusion protein inhibitors; Virus internalisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Aspergillosis; Cytomegalovirus infections
Most Recent Events
- 04 Jun 2008 Development of PTX3 is ongoing